Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder
NCT ID: NCT02673047
Last Updated: 2016-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
474 participants
OBSERVATIONAL
2016-02-29
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)
NCT04075578
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
NCT02161159
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
NCT00311376
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
NCT01852058
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
NCT02010788
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Botox®
Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.
botulinum toxin Type A
Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
botulinum toxin Type A
Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site D'Aix En Provence
Aix-en-Provence, , France
CL Toulouse Lautrec
Albi, , France
CHU Angers
Angers, , France
CH Angouleme
Angoulême, , France
CH Avranches Granville
Avranches, , France
CH Bagnols Sur Ceze
Bagnols-sur-Cèze, , France
CH Belfort
Belfort, , France
CHU Besancon
Besançon, , France
CL Saint Augustin
Bordeaux, , France
CHU Bordeaux
Bordeaux, , France
CH de Cahors
Cahors, , France
CH Châlons-en-Champagne
Châlons-en-Champagne, , France
CHU Clermont Ferrand
Clermont-Ferrand, , France
CH Colmar
Colmar, , France
CHU Mondor (APHP)
Créteil, , France
CH Hopale Ctre Calot/Helio
Cucq, , France
CHU Dijon
Dijon, , France
CHI E.Durkheim Plateau de La Justice
Épinal, , France
CH Raymond Poincare (APHP)
Garches, , France
CH Renee Sabran Hyeres (HCL)
Giens-Hyeres, , France
GH de la Rochelle Ré-Aunis
La Rochelle, , France
CH Bicêtre (APHP)
Le Kremlin-Bicêtre, , France
CH Le Mans
Le Mans, , France
CHU Limoges
Limoges, , France
CL Mutualiste Porte de L'Orient
Lorient, , France
CH de la Conception (APHM)
Marseille, , France
CH Mont de Marsan
Mont-de-Marsan, , France
CL Beau Soleil
Montpellier, , France
CHU Montpellier
Montpellier, , France
CH Mulhouse
Mulhouse, , France
CHU Nimes
Nîmes, , France
GH Saint Joseph
Paris, , France
CH Tenon (APHP)
Paris, , France
CH Lyon Sud (HCL)
Pierre-Bénite, , France
CH de Pontoise
Pointoise Cedex, , France
USLD de Lusignan
Poitiers, , France
CH Annecy
Pringy, , France
SIH Privas La Voulte
Privas, , France
Polyclinique Les Bleuets
Reims, , France
CHU de Rennes
Rennes, , France
CHU de Rouen
Rouen, , France
CL de L'Alliance Saint Cyr/Loire
Saint Cyr/Loire, , France
CH Saint-Avold
Saint-Avold, , France
CL Mutualiste Chirurgicale
Saint-Etienne, , France
CH de Saintonge (Saintes)
Saintes, , France
Hôpital Civil / Nouvel Hôpital Civil
Strasbourg, , France
CH Foch
Suresnes, , France
Clinique de l'Ormeau Pyrénées
Tarbes, , France
CHU Toulouse
Toulouse, , France
CHU Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAF/AGN/NS/OAB/006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.